Cargando…
A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002324/ https://www.ncbi.nlm.nih.gov/pubmed/29626322 http://dx.doi.org/10.1007/s13555-018-0235-4 |
_version_ | 1783332176658432000 |
---|---|
author | Gómez-García, Francisco Ruano, Juan Gay-Mimbrera, Jesús Aguilar-Luque, Macarena Sanz-Cabanillas, Juan L. Hernández Romero, José L. Garcia-Nieto, Antonio Velez |
author_facet | Gómez-García, Francisco Ruano, Juan Gay-Mimbrera, Jesús Aguilar-Luque, Macarena Sanz-Cabanillas, Juan L. Hernández Romero, José L. Garcia-Nieto, Antonio Velez |
author_sort | Gómez-García, Francisco |
collection | PubMed |
description | INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes. This is because evidence-based guidelines rank interventions according to cost-effectiveness. However, evidence on this topic is scarce for several reasons. First, although randomized clinical trials currently provide the best evidence, they are not always available. Second, there are no secondary scientific studies that summarize the use of IL-1-targeting agents in dermatology. We therefore sought to develop an a priori protocol for broadly reviewing the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases. METHODS: We used the latest methodology to perform a scoping review as described in the Joanna Briggs Institute manual. RESULTS/DISCUSSION: Developing and applying a methodology for evidence synthesis promotes reproducibility and increases the validity of secondary scientific investigations, making it the optimal strategy for scientifically synthesizing a broad field such as the indications for and the mechanisms of action, efficacies, safety, and costs of IL-1-targeting drugs in the treatment of dermatological diseases. Quantitative synthesis facilitates the detection of knowledge gaps and the identification of new questions that can be addressed through systematic reviews. We present an a priori protocol for exploring the available evidence on this topic. |
format | Online Article Text |
id | pubmed-6002324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-60023242018-06-29 A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety Gómez-García, Francisco Ruano, Juan Gay-Mimbrera, Jesús Aguilar-Luque, Macarena Sanz-Cabanillas, Juan L. Hernández Romero, José L. Garcia-Nieto, Antonio Velez Dermatol Ther (Heidelb) Review INTRODUCTION: The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes. This is because evidence-based guidelines rank interventions according to cost-effectiveness. However, evidence on this topic is scarce for several reasons. First, although randomized clinical trials currently provide the best evidence, they are not always available. Second, there are no secondary scientific studies that summarize the use of IL-1-targeting agents in dermatology. We therefore sought to develop an a priori protocol for broadly reviewing the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases. METHODS: We used the latest methodology to perform a scoping review as described in the Joanna Briggs Institute manual. RESULTS/DISCUSSION: Developing and applying a methodology for evidence synthesis promotes reproducibility and increases the validity of secondary scientific investigations, making it the optimal strategy for scientifically synthesizing a broad field such as the indications for and the mechanisms of action, efficacies, safety, and costs of IL-1-targeting drugs in the treatment of dermatological diseases. Quantitative synthesis facilitates the detection of knowledge gaps and the identification of new questions that can be addressed through systematic reviews. We present an a priori protocol for exploring the available evidence on this topic. Springer Healthcare 2018-04-06 /pmc/articles/PMC6002324/ /pubmed/29626322 http://dx.doi.org/10.1007/s13555-018-0235-4 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Gómez-García, Francisco Ruano, Juan Gay-Mimbrera, Jesús Aguilar-Luque, Macarena Sanz-Cabanillas, Juan L. Hernández Romero, José L. Garcia-Nieto, Antonio Velez A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety |
title | A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety |
title_full | A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety |
title_fullStr | A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety |
title_full_unstemmed | A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety |
title_short | A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety |
title_sort | scoping review protocol to explore the use of interleukin-1-targeting drugs for the treatment of dermatological diseases: indications, mechanism of action, efficacy, and safety |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002324/ https://www.ncbi.nlm.nih.gov/pubmed/29626322 http://dx.doi.org/10.1007/s13555-018-0235-4 |
work_keys_str_mv | AT gomezgarciafrancisco ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT ruanojuan ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT gaymimbrerajesus ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT aguilarluquemacarena ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT sanzcabanillasjuanl ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT hernandezromerojosel ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT garcianietoantoniovelez ascopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT gomezgarciafrancisco scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT ruanojuan scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT gaymimbrerajesus scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT aguilarluquemacarena scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT sanzcabanillasjuanl scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT hernandezromerojosel scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety AT garcianietoantoniovelez scopingreviewprotocoltoexploretheuseofinterleukin1targetingdrugsforthetreatmentofdermatologicaldiseasesindicationsmechanismofactionefficacyandsafety |